| Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population |
40 |
| Opioid medication discontinuation and risk of adverse opioid-related health care events |
23 |
| Telemedicine-delivered treatment interventions for substance use disorders: A systematic review |
23 |
| Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees |
19 |
| Gender differences in trends for heroin use and nonmedical prescription opioid use, 2007-2014 |
18 |
| Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States |
17 |
| Developing an opioid use disorder treatment cascade: A review of quality measures |
16 |
| Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone |
16 |
| Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review |
15 |
| Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap |
12 |
| Opioid recovery initiation: Pilot test of a peer outreach and modified Recovery Management Checkup intervention for out-of-treatment opioid users |
12 |
| Expected and actual fentanyl exposure among persons seeking opioid withdrawal management |
12 |
| Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore |
11 |
| Experiences of care among individuals with opioid use disorder-associated endocarditis and their healthcare providers: Results from a qualitative study |
11 |
| Group-based treatment of opioid use disorder with buprenorphine: A systematic review |
11 |
| Peer navigation and take-home naloxone for opioid overdose emergency department patients: Preliminary patient outcomes |
11 |
| Group treatment for substance use disorder in adults: A systematic review and meta-analysis of randomized-controlled trials |
11 |
| Associations between marijuana use and tobacco cessation outcomes in young adults |
10 |
| In-hospital illicit drug use, substance use disorders, and acceptance of residential treatment in a prospective pilot needs assessment of hospitalized adults with severe infections from injecting drugs |
10 |
| A longitudinal study of the comparative efficacy of Women for Sobriety, LifeRing, SMART Recovery, and 12-step groups for those with AUD |
10 |
| Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system |
10 |
| Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington |
9 |
| Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis |
9 |
| Behavioral health treatment utilization among individuals with co-occurring opioid use disorder and mental illness: Evidence from a national survey |
9 |
| Factors associated with methadone maintenance therapy discontinuation among people who inject drugs |
9 |
| Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management |
9 |
| Court personnel attitudes towards medication-assisted treatment: A state-wide survey |
8 |
| Understanding barriers to specialty substance abuse treatment among Latinos |
8 |
| Randomized controlled pilot trial of supportive text messaging for alcohol use disorder patients |
8 |
| Whether, when, and to whom?: An investigation of comfort with disclosing alcohol and other drug histories in a nationally representative sample of recovering persons |
8 |
| Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review |
8 |
| What works for whom and why: A narrative systematic review of interventions for reducing post-traumatic stress disorder and problematic substance use among women with experiences of interpersonal violence |
8 |
| Differential relationships of PTSD and childhood trauma with the course of substance use disorders |
8 |
| No more falling through the cracks: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder |
7 |
| Patient predictors of substance use disorder treatment initiation in primary care |
7 |
| Home-based delivery of XR-NTX in youth with opioid addiction |
7 |
| Variability in motivational interviewing adherence across sessions, providers, sites, and research contexts |
7 |
| Medicaid coverage in substance use disorder treatment after the affordable care act |
7 |
| Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: A qualitative study of a bridge clinic |
7 |
| Comparison between buprenorphine provider availability and opioid deaths among US counties |
7 |
| Health literacy in substance use disorder treatment: A latent profile analysis |
7 |
| Specific aspects of cognitive impulsivity are longitudinally associated with lower treatment retention and greater relapse in therapeutic community treatment |
7 |
| Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder |
7 |
| Buprenorphine in the United States: Motives for abuse, misuse, and diversion |
6 |
| Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial |
6 |
| Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans |
6 |
| Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers |
6 |
| Evidence-based treatment for opioid use disorders: A national study of methadone dose levels, 2011-2017 |
6 |
| Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods |
6 |
| US hospital discharges documenting patient opioid use disorder without opioid overdose or treatment services, 2011-2015 |
6 |
